3 assets in Ovarian Brenner Tumor

Therapeutic assets addressing Ovarian Brenner Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Brenner Tumor	Gynecologic Oncology Group	P3	BB (70)
Docetaxel Ovarian Brenner Tumor	National Cancer Institute (NCI)	P3	BB (65)
Adavosertib Ovarian Brenner Tumor	National Cancer Institute (NCI)	P2	CCC (52)